Bernstein Reiterates Outperform Rating on DexCom (DXCM) Following FDA Approval
Tweet Send to a Friend
Bernstein SocGen Group analyst Lee Hambright reiterated an Outperform rating and $100.00 price target on DexCom (NASDAQ: DXCM).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
